: Prospective study on metabolic factors and risk of prostate cancer.
Cancer 2012,118(24):6199–6206.PubMedCrossRef 20. Beebe-Dimmer JL, Nock NL, Crenigacestat purchase Neslund-Dudas C, Rundle A, Bock CH, Tang D, Jankowski M, Rybicki BA: Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009,74(1):185–190.PubMedCrossRef 21. Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, La Vecchia C: The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 2011,21(11):835–841.PubMedCrossRef 22. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D: Metabolic Syndrome and Risk of Cancer: A systematic review and meta-analysis. Diabetes Care 2012,35(11):2402–2411.PubMedCrossRef 23. Castillejos-Molina R, Rodriguez-Covarrubias F, Sotomayor M, Gomez-Alvarado MO, Villalobos-Gollas
M, Gabilondo F, Feria-Bernal G: Impact of metabolic syndrome on biochemical recurrence of prostate cancer after radical prostatectomy. Urol Int 2011,87(3):270–275.PubMedCrossRef 24. Kheterpal E, Sammon JD, Diaz M, Bhandari A, Trinh QD, Pokala N, Sharma P, Menon M, Agarwal PK: Effect of metabolic syndrome on pathologic features of prostate cancer. Urol Oncol 2012. Epub ahead of print 25. De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A, Tubaro A: Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011. Epub ahead of print 26. Morote Mocetinostat price J, Ropero J, Planas J, Bastaros JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventos J, et al.: Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int 2012. Epub ahead of print 27. Post JM, Beebe-Dimmer JL, Morgenstern H, Neslund-Dudas C, Bock CH, Nock N, Rundle A, Jankowski M, Rybicki BA: The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy. Prostate Cancer 2011, 2011:245642.PubMedCrossRef 28. Jeon KP, Jeong TY, Lee SY, Hwang SW, Shin JH, Kim DS: Prostate cancer in patients with metabolic
syndrome is associated G protein-coupled receptor kinase with low grade Gleason score when diagnosed on biopsy. Korean J Urol 2012,53(9):593–597.PubMedCrossRef 29. B.K H: The characteristics of prostate cancer with metabolic syndrome in Korean men. Korean J Urol 2007,48(6):585–591.CrossRef 30. Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, Blair SN: Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 2009,45(10):1831–1838.PubMedCrossRef 31. Antonio C, Francesco C, Cosimo DN, Andrea T, Rocco D: Patients with metabolic syndrome and TGF-beta inhibitor widespread high grade prostatic intraepithelial neoplasia are at a higher risk factor of prostate cancer on re-biopsy: a prospective single cohort study. Urol Oncol 2012. Epub ahead of print 32. Hammarsten J, Hogstedt B: Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005,41(18):2887–2895.PubMedCrossRef 33.